Parameter regression (standard error) (quantitative variable) | Median (range) vitamin D levels (binary variables) | p Value | |
---|---|---|---|
Age | 0.19 (0.07) | 0.007 | |
Gender | |||
Male | 24 (9–48) | 0.06 | |
Female | 18 (5–42) | ||
Ethnicity | |||
Europe | 17 (5–42) | 0.19 | |
Others | 20 (5–48) | ||
BMI | −0.22 (0.14) | 0.12 | |
Current smokers | |||
No | 19 (5–48) | 0.64 | |
Yes | 17 (5–42) | ||
Season | |||
Summer | 24 (8–41) | 0.001 | |
Others | 17 (5–48) | ||
Disease duration | 0.17 (0.11) | 0.12 | |
Photosensitivity | |||
No | 23 (7–42) | 0.04 | |
Yes | 17 (5–48) | ||
Malar rash | |||
No | 20 (5–42) | 0.8 | |
Yes | 18 (5–48) | ||
Discoid lupus | |||
No | 19 (5–48) | 0.8 | |
Yes | 19 (5–41) | ||
Creatinine clearance | −0.048 (0.02) | 0.03 | |
Anti-dsDNA (Farr assay) | −0.014 (0.03) | 0.61 | |
Anti-dsDNA (ELISA) | −0.006 (0.005) | 0.29 | |
C3 levels | −1.17 (3.34) | 0.72 | |
Associated APS | |||
No | 18 (5–48) | 0.007 | |
Yes | 25 (9–41) | ||
Corticosteroid dosage | 0.03 (0.12) | 0.8 | |
Ever immunosuppressant drugs use | |||
No | 19 (5–42) | 0.24 | |
Yes | 23 (5–48) | ||
HCQ concentration | −0.0007 (0.001) | 0.66 | |
Current anticoagulant treatment | |||
No | 19 (5–48) | 0.1 | |
Yes | 31 (15–40) |
25(OH)D, 25-hydroxyvitamin D; APS, antiphospholipid syndrome; BMI, body mass index; HCQ, hydroxychloroquine.